+

NO20081073L - Makrocykliske inhibitorer av hepatitt C virus - Google Patents

Makrocykliske inhibitorer av hepatitt C virus

Info

Publication number
NO20081073L
NO20081073L NO20081073A NO20081073A NO20081073L NO 20081073 L NO20081073 L NO 20081073L NO 20081073 A NO20081073 A NO 20081073A NO 20081073 A NO20081073 A NO 20081073A NO 20081073 L NO20081073 L NO 20081073L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
inhibitors
macrocyclic inhibitors
formula
Prior art date
Application number
NO20081073A
Other languages
English (en)
Other versions
NO342393B1 (no
Inventor
Herman Augustinus De Kock
Dominique Louis Nestor Ghislain Surleraux
Abdellah Tahri
Kenneth Alan Simmen
Sandrine Marie Helene Vendeville
Lili Hu
Pierre Jean-Marie Bernard Raboisson
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Asa Annicka Kristina Rosenquist
Vladimir Ivanov
Michael Pelcman
Anna Karin Gertrud Linnea Belfrage
Per-Ola Mikael Johansson
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37067620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081073(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081073L publication Critical patent/NO20081073L/no
Publication of NO342393B1 publication Critical patent/NO342393B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Inhibitorer av HCV-replikasjon med formel (I) og N-oksidene, saltene og stereoisomerene, hvori hver stiplet linje representerer en eventuell dobbelbinding; hvori X, R1-R6 og n er som definert i beskrivelsen; farmasøytiske sammensetninger som inneholder forbindelser (I) og fremgangsmåter for fremstilling av forbindelser (I). Biotilgjengelige kombinasjoner av inhibitorene av HCV med formel (I) med ritonavir er også tilveiebrakt.
NO20081073A 2005-07-29 2008-02-29 Makrocykliske inhibitorer av hepatitt C virus NO342393B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05107074 2005-07-29
EP05107417 2005-08-11
EP06101280 2006-02-03
PCT/EP2006/064820 WO2007014926A1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Publications (2)

Publication Number Publication Date
NO20081073L true NO20081073L (no) 2008-04-28
NO342393B1 NO342393B1 (no) 2018-05-14

Family

ID=37067620

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20081073A NO342393B1 (no) 2005-07-29 2008-02-29 Makrocykliske inhibitorer av hepatitt C virus
NO2018037C NO2018037I1 (no) 2005-07-29 2018-10-24 Simeprevir, eller salt derav, innbefattende natrium-simeprevir

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2018037C NO2018037I1 (no) 2005-07-29 2018-10-24 Simeprevir, eller salt derav, innbefattende natrium-simeprevir

Country Status (41)

Country Link
US (9) US8148399B2 (no)
EP (3) EP2322516B1 (no)
JP (1) JP4797067B2 (no)
KR (1) KR101059419B1 (no)
CN (3) CN103030636B (no)
AP (1) AP2406A (no)
AR (1) AR055359A1 (no)
AT (1) ATE494288T1 (no)
AU (1) AU2006274865B2 (no)
BR (1) BRPI0614654B1 (no)
CA (1) CA2616580C (no)
CR (1) CR9783A (no)
CY (3) CY1112006T1 (no)
DE (1) DE602006019439D1 (no)
DK (2) DK2322516T3 (no)
EA (1) EA015131B1 (no)
EC (1) ECSP088150A (no)
ES (1) ES2555230T3 (no)
GT (1) GT200600339A (no)
HK (2) HK1116771A1 (no)
HN (1) HN2008000134A (no)
HR (2) HRP20110237T1 (no)
HU (2) HUE027156T2 (no)
IL (2) IL188227A (no)
LU (1) LU92568I2 (no)
ME (2) ME02415B (no)
MY (1) MY144217A (no)
NI (1) NI200800036A (no)
NO (2) NO342393B1 (no)
NZ (1) NZ564550A (no)
PE (1) PE20070211A1 (no)
PL (2) PL1912999T3 (no)
PT (2) PT1912999E (no)
RS (2) RS54473B1 (no)
SG (1) SG163617A1 (no)
SI (2) SI1912999T1 (no)
SV (1) SV2008002642A (no)
TW (1) TWI358411B (no)
UY (1) UY29703A1 (no)
WO (1) WO2007014926A1 (no)
ZA (1) ZA200800857B (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2005207816C1 (en) 2004-01-30 2015-05-07 Medivir Ab HCV NS-3 serine protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2359939T3 (es) * 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ES2449540T3 (es) 2005-07-29 2014-03-20 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
PL1919898T3 (pl) * 2005-07-29 2011-06-30 Tibotec Pharm Ltd Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
ME01318B (me) * 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
ES2456617T3 (es) * 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200808788A (en) 2006-04-19 2008-02-16 Astellas Pharma Inc Azolecarboxamide derivative
KR20090026216A (ko) * 2006-07-07 2009-03-11 길리애드 사이언시즈, 인코포레이티드 항바이러스 포스피네이트 화합물
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090079881A (ko) 2006-11-17 2009-07-22 티보텍 파마슈티칼즈 리미티드 Ｃ형 간염 바이러스의 마크로사이클릭 억제제
NZ577568A (en) * 2007-02-01 2012-02-24 Tibotec Pharm Ltd Polymorphic forms of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13 -diazatricyclo[13.3.0.0^4,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide
CN103145699B (zh) * 2007-02-01 2015-09-09 爱尔兰詹森科学公司 用于制备hcv的大环蛋白酶抑制剂的方法和中间体
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
RU2461551C2 (ru) * 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
KR20100118991A (ko) * 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
EP2268619A4 (en) 2008-03-20 2012-04-04 Enanta Pharm Inc FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PE20110343A1 (es) 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
WO2010031832A2 (en) * 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201036612A (en) 2008-12-22 2010-10-16 Gilead Sciences Inc Antiviral compounds
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
CA2745565C (en) 2008-12-23 2017-03-07 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
CA2748016A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
EP2401272B1 (en) 2009-02-27 2017-01-11 Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of hcv
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
JP2012520891A (ja) * 2009-03-19 2012-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スルホニルキノリンの製造方法
WO2010118078A1 (en) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CA2769652A1 (en) * 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
IN2012DN02693A (no) * 2009-09-28 2015-09-04 Intermune Inc
MX2012004971A (es) 2009-10-30 2012-06-12 Boehringer Ingelheim Int Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063501A1 (en) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
MX2012010678A (es) 2010-03-16 2012-10-15 Janssen Pharmaceuticals Inc Procedimientos e intermediarios para preparar un inhibidor macrociclico de proteasa del virus de la hepatitis c.
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SI2609923T1 (sl) 2010-03-31 2017-10-30 Gilead Pharmasset Llc Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
AU2011239974B2 (en) * 2010-04-13 2015-12-03 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of HCV, a non-nucleoside and a nucleoside
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
AR087814A1 (es) * 2011-09-16 2014-04-16 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
JP6235473B2 (ja) 2011-09-22 2017-11-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド 大環状ｈｃｖプロテアーゼ阻害剤を製造するための方法および中間体
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2848377A1 (en) 2011-10-28 2013-05-02 Janssen Pharmaceuticals, Inc. Improved process for preparing an intermediate of the macrocyclic protease inhibitor tmc 435
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9346785B2 (en) 2012-01-11 2016-05-24 Abbvie Inc. Process for making HCV protease inhibitors
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015003913A2 (pt) * 2012-08-31 2017-07-04 Janssen Pharmaceuticals Inc combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3057976A1 (en) 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015180253A1 (zh) * 2014-05-29 2015-12-03 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105175406B (zh) * 2014-06-09 2019-06-04 深圳翰宇药业股份有限公司 Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
CN105237528B (zh) * 2014-06-09 2019-06-04 深圳翰宇药业股份有限公司 Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
WO2017064680A1 (en) * 2015-10-16 2017-04-20 Lupin Limited An improved process for the preparation of simeprevir sodium and intermediate thereof
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2018028541A1 (zh) * 2016-08-12 2018-02-15 深圳市塔吉瑞生物医药有限公司 一种取代的喹啉化合物及其药物组合物及应用
JP2022541761A (ja) 2019-07-15 2022-09-27 メドイミューン・リミテッド タンパク質二量体化の三分子システム及び使用方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
CA1283906C (en) 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5831108A (en) * 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
BR9708735A (pt) 1996-04-23 1999-08-03 Vertex Pharma Derivados de uréia como inibidores da enzina impdh
CN1133649C (zh) * 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
NZ503262A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6038157A (en) 1998-05-28 2000-03-14 Inductotherm Corp. Fault tolerant power supply circuit
CA2331920A1 (en) 1998-06-24 1999-12-29 International Reagent Corporation Hcv-derived rna polymerase gene
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
WO2001074768A2 (en) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
IL162828A0 (en) 2002-01-23 2005-11-20 Schering Corp Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
EP1497282A2 (en) 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
ATE503764T1 (de) * 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AUPS328002A0 (en) 2002-06-28 2002-07-18 Novapharm Research (Australia) Pty Ltd Water treatment
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1558730B1 (en) 2002-10-29 2008-01-30 Boehringer Ingelheim International GmbH Inhibitor-resistant hcv ns3 protease
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
JP2007524576A (ja) 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状のｃ型肝炎セリンプロテアーゼ阻害剤
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
RS20050741A (en) 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for hepatitis c viral protease inhibitors
US7148347B2 (en) 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
PT1615613E (pt) 2003-04-18 2010-02-09 Enanta Pharm Inc Inibidores da serina protease da hepatite c macrocíclicos de quinoxalinilo
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
UY28525A1 (es) * 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
DE10344793A1 (de) 2003-09-26 2005-04-14 Rieter Automatik Gmbh Vorrichtung zum Granulieren thermoplastischer Kunststoffe
AU2005207816C1 (en) * 2004-01-30 2015-05-07 Medivir Ab HCV NS-3 serine protease inhibitors
SE0400199D0 (sv) * 2004-01-30 2004-01-30 Medivir Ab HCV Protease inhbitors
JP2008513454A (ja) * 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
ES2456617T3 (es) 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
ME01318B (me) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
RU2441870C2 (ru) 2005-07-29 2012-02-10 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ES2359939T3 (es) 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PL1919898T3 (pl) * 2005-07-29 2011-06-30 Tibotec Pharm Ltd Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
RU2419619C2 (ru) * 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
ES2449540T3 (es) * 2005-07-29 2014-03-20 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
NZ577568A (en) 2007-02-01 2012-02-24 Tibotec Pharm Ltd Polymorphic forms of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13 -diazatricyclo[13.3.0.0^4,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide
AU2011239974B2 (en) 2010-04-13 2015-12-03 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of HCV, a non-nucleoside and a nucleoside
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap

Also Published As

Publication number Publication date
CA2616580C (en) 2009-10-06
SI2322516T1 (sl) 2016-02-29
EP2322516A1 (en) 2011-05-18
ZA200800857B (en) 2014-07-30
US8349869B2 (en) 2013-01-08
CY2014044I1 (el) 2016-04-13
NO342393B1 (no) 2018-05-14
ES2555230T3 (es) 2015-12-29
US9623022B2 (en) 2017-04-18
HUS1400054I1 (hu) 2016-09-28
US9353103B2 (en) 2016-05-31
EP2322516B1 (en) 2015-09-23
TW200745117A (en) 2007-12-16
AR055359A1 (es) 2007-08-22
CY1112006T1 (el) 2015-11-04
PT2322516E (pt) 2016-01-15
PL1912999T3 (pl) 2011-06-30
NO2018037I1 (no) 2018-10-24
EA200800476A1 (ru) 2008-08-29
US20130217725A1 (en) 2013-08-22
US20170226111A1 (en) 2017-08-10
CR9783A (es) 2008-09-09
IL188227A0 (en) 2008-03-20
JP4797067B2 (ja) 2011-10-19
MY144217A (en) 2011-08-15
WO2007014926A1 (en) 2007-02-08
PL2322516T3 (pl) 2016-03-31
US9040562B2 (en) 2015-05-26
ME02415B (me) 2016-09-20
ME01231B (me) 2013-06-20
IL188227A (en) 2015-08-31
CN101228169B (zh) 2013-03-13
CN101228169A (zh) 2008-07-23
ATE494288T1 (de) 2011-01-15
RS51743B (en) 2011-10-31
HRP20151326T1 (hr) 2016-01-29
KR101059419B1 (ko) 2011-08-29
AP2406A (en) 2012-05-02
UY29703A1 (es) 2007-05-31
SG163617A1 (en) 2010-08-30
KR20080042084A (ko) 2008-05-14
US20090281140A1 (en) 2009-11-12
US20130089520A1 (en) 2013-04-11
SI1912999T1 (sl) 2011-05-31
HUE027156T2 (en) 2016-08-29
CY1117392T1 (el) 2017-04-26
AU2006274865A1 (en) 2007-02-08
LU92568I2 (fr) 2015-10-29
RS54473B1 (en) 2016-06-30
DK1912999T3 (da) 2011-04-18
EP1912999B1 (en) 2011-01-05
BRPI0614654A2 (pt) 2011-04-12
EP1912999A1 (en) 2008-04-23
CN103030636A (zh) 2013-04-10
US8148399B2 (en) 2012-04-03
JP2009502889A (ja) 2009-01-29
BRPI0614654B1 (pt) 2019-03-12
AU2006274865B2 (en) 2010-06-24
HK1183872A1 (zh) 2014-01-10
CY2014044I2 (el) 2016-04-13
US20150218153A1 (en) 2015-08-06
GT200600339A (es) 2007-09-05
PT1912999E (pt) 2011-03-31
ECSP088150A (es) 2008-02-20
US20110295012A1 (en) 2011-12-01
IL240244A0 (en) 2015-09-24
US8754106B2 (en) 2014-06-17
NZ564550A (en) 2010-06-25
US8153800B2 (en) 2012-04-10
EA015131B1 (ru) 2011-06-30
US20160235737A1 (en) 2016-08-18
TWI358411B (en) 2012-02-21
US8741926B2 (en) 2014-06-03
US9856265B2 (en) 2018-01-02
HN2008000134A (es) 2010-11-03
HK1116771A1 (en) 2009-01-02
HRP20110237T1 (hr) 2011-05-31
CA2616580A1 (en) 2007-02-08
CN102627639A (zh) 2012-08-08
CN102627639B (zh) 2017-04-12
CN103030636B (zh) 2016-03-02
SV2008002642A (es) 2008-08-29
NI200800036A (es) 2016-02-23
PE20070211A1 (es) 2007-05-12
DK2322516T3 (en) 2015-12-14
DE602006019439D1 (de) 2011-02-17
EP2937339A1 (en) 2015-10-28
US20120171157A1 (en) 2012-07-05
US20140255347A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
NO20081073L (no) Makrocykliske inhibitorer av hepatitt C virus
NO20081071L (no) Makrocykliske inhibitorer av hepatitt C virus
NO20090628L (no) Pyridizinon derivativater
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
ATE524465T1 (de) 2-carboxy-thiophen-derivate als viruzide
NO20074613L (no) Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
SG164376A1 (en) Hcv ns3 protease inhibitors
UA100840C2 (ru) Композиция для лечения вирусного гепатита
WO2008021936A3 (en) Hepatitis c virus inhibitors
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
NO20074703L (no) Antibakterielle piperidinderivater
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
EA200900297A1 (ru) Ингибиторы вируса гепатита с
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
TW200745004A (en) Novel compounds, their preparation and use
EA200901241A1 (ru) Соединения для лечения гепатита с
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
WO2006092599A3 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
TW200800969A (en) Compounds
WO2006087544A3 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDIVIR AB, IE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDIVIR AB, IE

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: SIMEPREVIR, ELLER SALT DERAV, INNBEFATTENDE NATRIUM-SIMEPREVIR; NAT. REG. NO/DATE: NO , EU/1/14/924 20140516

Spc suppl protection certif: 2018037

Filing date: 20181024

SPCW Withdrawal, rejection or dismissal of supplementary protection certificate

Spc suppl protection certif: 2018037

MM1K Lapsed by not paying the annual fees
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载